Condition: High Grade Serous Ovarian Cancer · Sponsor: Institute of Cancer Research, United Kingdom
Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells for creating new DNA when they multiply. Blocking the action of thymidylate synthase with a drug like Idetrexed may therefore stop cancers from growing by damaging DNA in cancer cells. Olaparib is a type of drug called a "PARP inhibitor". It prevents cells repairing DNA damage. This leads to cells dying. Combining Idetrexed and olaparib should increase the number of cancer cells dying, especially those cells that have a lot of folate receptors. Cancer cells with a high number of folate receptors should be targeted more than normal healthy cells.
This description comes directly from the study's public registry record.
Alexander Cowley, Ph.D. · +44 20 3437 6927 · idol@icr.ac.uk
Anna Zachariou, Ph.D. · idol@icr.ac.uk
Always discuss trial participation with your own doctor first.
| Addenbrooke's Hospital | Cambridge, Cambridgeshire, United Kingdom | Not Yet Recruiting |
| Royal Marsden Hospital - Drug Development Unit | Sutton, London, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, Wales, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976892